Shattuck Labs Secures $103 Million in Private Placement to Advance Phase 2 Trials and Expands Board of Directors
Shattuck Labs Inc. has secured approximately $103 million in a private placement led by OrbiMed to support its operations until 2029. The funding will advance its SL-325 antibody through Phase 2 trials for Inflammatory Bowel Disease and other autoimmune diseases. Additionally, the company has expanded its Board of Directors by appointing Dan Baker, M.D., and Mona Ashiya, Ph.D., indicating a strategic focus on immunology and inflammation.
Shattuck Labs Inc., a biotechnology company focused on developing novel therapeutics for inflammatory and immune-mediated diseases, has announced the closing of a private placement of up to approximately $103 million, led by OrbiMed. The proceeds from this financing, assuming full exercise of common stock warrants, are expected to support the company’s operations until 2029. This funding will advance SL-325, a potentially first-in-class DR3 blocking antibody, through multiple Phase 2 clinical trials, including those for Inflammatory Bowel Disease and potentially other autoimmune diseases. Along with this financial milestone, Shattuck Labs has appointed Dan Baker, M.D., an industry expert, and Mona Ashiya, Ph.D., from OrbiMed, to its Board of Directors, signaling a strategic shift towards an immunology and inflammation-centered focus. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9518069-en) on August 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
